Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 18, 2012, Pages 5496-5506

  Ohashi, Tomohiro ^a   Oguro, Yuya ^a   Tanaka, Toshio ^a   Shiokawa, Zenyu ^a   Shibata, Sachio ^a   Sato, Yoshihiko ^a   Yamakawa, Hiroko ^a   Hattori, Harumi ^a   Yamamoto, Yukiko ^a   Kondo, Shigeru ^a   Miyamoto, Maki ^a   Tojo, Hideaki ^a   Baba, Atsuo ^a   Sasaki, Satoshi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Hedgehog; Hh signaling inhibitor; Pyrrolo 3,2 c quinoline 4 one

Indexed keywords

3 ETHOXY 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) N (2 PYRROLIDIN 1 YLETHYL) 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; 3 METHOXY 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) N (2 PIPERIDIN 1 YLETHYL) 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; 3 METHOXY 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) N (2 PYRROLIDIN 1 YLETHYL) 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; 3 METHOXY 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) N PIPERIDIN 4 YL 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; 3 METHOXY 1 METHYL N (2 MORPHOLINO 4 YLETHYL) 4 OXO 5 (2 OXO 2 PHENYLETHYL) 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; ANTINEOPLASTIC AGENT; MESSENGER RNA; N [1 (2 HYDROXYETHYL)PIPERIDIN 4 YL] 3 METHOXY 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; N [1 (2 HYDROXYETHYL)PIPERIDIN 4 YL] 3 METHOXY 1 METHYL 4 OXO 5 (2 OXOBUTYL) 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; N [1 (2 HYDROXYETHYL)PIPERIDIN 4 YL] 3 METHOXY 1 METHYL 4 OXO 5 (2 PHENYLETHYL) 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; N [1 (HYDROXYACETYL)PIPERIDIN 4 YL] 3 METHOXY 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) 4,5 DIHYDRO 1H PYRROLO[3,2 C]QUINOLINE 2 CARBOXAMIDE; PROTEIN INHIBITOR; PYRROLO[3,2 C]QUINOLINE 4 ONE DERIVATIVE; SONIC HEDGEHOG PROTEIN; THIENO[3,2 C]QUINOLINE 4 ONE DERIVATIVE; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; GENE; GENE EXPRESSION REGULATION; GLI1 GENE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEDULLOBLASTOMA; NONHUMAN; PANCREAS TUMOR; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT;

4-QUINOLONES; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HEDGEHOG PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MEDULLOBLASTOMA; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NIH 3T3 CELLS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HOMOLOGOUS;

ERINACEIDAE; MURINAE;

EID: 84866246074     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.07.039     Document Type: Article

References (18)

1. X. Zeng, J.A. Goetz, L.M. Suber, W.J. Scott Jr, C.M. Schreiner, and D.J. Robbins Nature 411 2001 716
2. D.M. Stone, M. Hynes, M. Armanini, T.A. Swanson, Q. Gu, R.L. Johnson, M.P. Scott, D. Pennica, A. Goddard, H. Phillips, M. Noll, J.E. Hooper, F. Sauvage, and A. Rosenthal Nature 384 1996 129
3. H. Tian, C.A. Callahan, K.J. DuPree, W.C. Darbonne, C.P. Ahn, S.J. Scales, and F. Sauvage Proc. Natl. Acad. Sci. USA 106 11 2009 4254
4. D.M. Berman, S.S. Karhadkar, A.R. Hallahan, J.I. Pritchard, C.G. Eberhart, D.N. Watkins, J.K. Chen, M.K. Cooper, J. Taipale, J.M. Olson, and P.A. Beachy Science 297 2002 1559
5. H.E. Epstein Nat. Rev. Cancer 8 2008 743
6. R.L. Yauch, S.E. Gould, S.J. Scales, T. Tang, H. Tian, C.P. Ahn, D. Marshall, L. Fu, T. Januario, D. Kallop, M. Nannini-Pepe, K. Kotkow, J.C. Marsters Jr., L.L. Rubin, and F.J. Sauvage Nature 455 2008 406
7. T. Mazumdar, J. DeVecchio, T. Shi, J. Jones, A. Agyeman, and J.A. Houghton Cancer Res. 71 2011 1092
8. A. Shaw, and W. Bushman J. Urol. 177 2007 832
9. S.P. Thayer, M.P. Magliano, P.W. Heiser, C.M. Nielsen, D.J. Roberts, G.Y. Lauwers, Y.P. Qi, S. Gysin, C.F. Castillo, V. Yajnik, B. Antoniu, M. McMahon, A.L. Warshaw, and M. Hebrok Nature 425 2003 851
10. J. Taipale, J.K. Chen, M.K. Cooper, B. Wang, R.K. Mann, L. Milenkovic, M.P. Scott, and P.A. Beachy Nature 406 2000 1005
11. S.S. Karhadkar, G.S. Bova, N. Abdallah, S. Dhara, D. Gardner, A. Maitra, J.T. Isaacs, D.M. Berman, and P.A. Beachy Nature 431 2004 707
12. Vismodegiv (Erivedge™) Prescription Information, 2012, Genetech USA, Inc, South San Francisco CA.
13. M.R. Tremblay, A. Lescarbeau, M.J. Grogan, E. Tan, G. Lin, B.C. Austad, L. Yu, M.L. Behnke, S.J. Nair, M. Hagel, K. White, J. Conley, J.D. Manna, T.M. Alvarez-Diez, J. Hoyt, C.N. Woodward, J.R. Sydor, M. Pink, J. MacDougall, M.J. Campbell, J. Cushing, J. Ferguson, M.S. Curtis, K. McGovern, M.A. Read, V.J. Palombella, J. Adams, and A.C. Castro J. Med. Chem. 52 2009 4400
14. S. Pan, X. Wu, J. Jiang, W. Gao, Y. Wan, D. Cheng, D. Han, J. Liu, N.P. Englund, Y. Wang, S. Peukert, K. Miller-Moslin, J. Yuan, R. Guo, M. Matsumoto, A. Vattay, Y. Jiang, J. Tsao, F. Sun, A.C. Pferdekamper, S. Dodd, T. Tuntland, W. Maniara, J.F. Kelleher III, Y. Yao, M. Warmuth, J. Williams, and M. Dorsch ACS Med. Chem. Lett. 3 2010 130
15. M.J. Munchhof, Q. Li, A. Shavnya, G.V. Borzillo, T.L. Boyden, C.S. Jones, S.D. LaGreca, L. Martinez-Alsina, N. Patel, K. Pelletier, L.A. Reiter, M.D. Robbins, and G.T. Tkalcevic ACS Med. Chem. Lett. 3 2012 106
16. K.P. Williams, P. Rayhorn, G. Chi-Rosso, E.A. Garber, K.L. Strauch, G.S.B. Horan, J.O. Reilly, D.P. Baker, F.R. Taylor, V. Koteliansky, and R.B. Pepinsky J. Cell. Sci. 112 23 1999 4405
17. E.H. Kerns, and L. Di Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization 2008 Academic press
18. K. Sasai, J.T. Romer, Y. Lee, D. Finkelstein, C. Fuller, P.J. McKinnon, and T. Curran Cancer Res. 66 2006 4215